Use of disulfiram and risk of cancer: A population-based case-control study

European Journal of Cancer Prevention

Volumn 23, Issue 3, 2014, Pages 225-232

  Askgaard, Gro ^a   Friis, Søren ^b   Hallas, Jesper ^c   Thygesen, Lau C ^d   Pottegård, Anton ^c  

^a Rigshospitalet   (Denmark)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Cancer; Case control study; Disulfiram; Nationwide

Indexed keywords

DISULFIRAM; DRUGS USED IN THE TREATMENT OF ADDICTION;

ADULT; AGED; ALCOHOL CONSUMPTION; ALCOHOLIC BEVERAGE; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER RISK; COLORECTAL CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG USE; EPIDEMIOLOGICAL DATA; FEMALE; HISTOLOGY; HUMAN; LIVER CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; MIDDLE AGED; MOUTH CANCER; POPULATION BASED CASE CONTROL STUDY; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER; REGISTER; RISK REDUCTION; SMOKING; TOBACCO; BREAST NEOPLASMS; CASE CONTROL STUDY; DENMARK; EPIDEMIOLOGY; NEOPLASMS; PROSTATIC NEOPLASMS; RISK FACTOR;

AGED; ALCOHOL DETERRENTS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; DENMARK; DISULFIRAM; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASMS; PROSTATIC NEOPLASMS; REGISTRIES; RISK FACTORS;

EID: 84897435105     PISSN: 09598278     EISSN: 14735709     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e3283647466     Document Type: Article

References (40)

1. Azzouni F, Mohler J. (2012). Role of 5-Alpha-reductase inhibitors in prostate cancer prevention and treatment. Urology 79:1197-205.
2. Baan R, Straif K, Grosse Y, Secretan B, El GF, Bouvard V, et al. (2007). Carcinogenicity of alcoholic beverages. Lancet Oncol 8:292-293.
3. Borup C, Kaiser A, Jensen E (1992). Long-Term Antabuse treatment: Tolerance and reasons for withdrawal. Acta Psychiatr Scand Suppl 369:47-49.
4. Cen D, Brayton D, Shahandeh B, Meyskens FL Jr, Farmer PJ (2004). Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells. J Med Chem 47:6914-6920.
5. Charlson ME, Pompei P, Ales KL, MacKenzie CR. (1987). A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40:373-383.
6. Chen D, Peng F, Cui QC, Daniel KG, Orlu S, Liu J, et al. (2005). Inhibition of prostate cancer cellular proteasome activity by a pyrrolidine dithiocarbamate-copper complex is associated with suppression of proliferation and induction of apoptosis. Front Biosci 10:2932-2939.
7. Chen D, Cui QC, Yang H, Dou QP (2006). Disulfiram, a clinically used anti-Alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res 66:10425-10433.
8. Chen WY (2011). Postmenopausal hormone therapy and breast cancer risk: Current status and unanswered questions. Endocrinol Metab Clin North Am 40:509-518, viii.
9. Conticello C, Martinetti D, Adamo L, Buccheri S, Giuffrida R, Parrinello N, et al. (2012). Disulfiram, an old drug with new potential therapeutic uses for human hematological malignancies. Int J Cancer 131:2197-2203.
10. Cvek B (2011). Targeting malignancies with disulfiram (Antabuse): Multidrug resistance, angiogenesis, and proteasome. Curr Cancer Drug Targets 11:332-337.
11. Davidsen M, Kjoller M, Helweg-Larsen K (2011). The Danish National Cohort Study (DANCOS). Scand J Public Health 39:131-135.
12. Dufour P, Lang JM, Giron C, Duclos B, Haehnel P, Jaeck D, et al. (1993). Sodium dithiocarb as adjuvant immunotherapy for high risk breast cancer: A randomized study. Biotherapy 6:9-12.
13. Gaist D, Sorensen HT, Hallas J (1997). The Danish prescription registries. Dan Med Bull 44:445-448.
14. Gjerstorff ML (2011). The Danish Cancer Registry. Scand J Public Health 39:42-45.
15. Gupta A, Driscoll MS (2010). Do hormones influence melanoma Facts and controversies. Clin Dermatol 28:287-292.
16. Jensen AO, Thomsen HF, Engebjerg MC, Olesen AB, Sorensen HT, Karagas MR (2008). Use of photosensitising diuretics and risk of skin cancer: A population-based case-control study. Br J Cancer 99:1522-1528.
17. Jensen VM, Rasmussen AW(2011). Danish Education Registers. Scand J Public Health 39:91-94.
18. Jorgensen KJ, Zahl PH, Gotzsche PC (2009). Overdiagnosis in organised mammography screening in Denmark. A comparative study. BMC Womens Health 9:36.
19. Jorgensen T, Herrstedt J, Friis S, Hallas J. (2012). Polypharmacy and drug use in elderly Danish cancer patients during 1996 to 2006. J Geriatr Oncol 3: 33-40.
20. Karin M (2006). Nuclear factor-kappa-B in cancer development and progression. Nature 441:431-436.
21. Kildemoes HW, Sorensen HT, Hallas J (2011). The Danish National Prescription Registry. Scand J Public Health 39:38-41.
22. Danish Health and Medicines Authority (2011). Available at: Http://www.med stat.dk. [Accessed 5 June 2011].
23. Leitzmann MF, Rohrmann S. (2012). Risk factors for the onset of prostatic cancer: Age, location, and behavioral correlates. Clin Epidemiol 4:1-11.
24. Lin J, Haffner MC, Zhang Y, Lee BH, Brennen WN, Britton J, et al. (2011). Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth. Prostate 71:333-343.
25. Lin LZ, Lin J (2011). Antabuse (disulfiram) as an affordable and promising anticancer drug. Int J Cancer 129:1285-1286.
26. Liu P, Brown S, Goktug T, Channathodiyil P, Kannappan V, Hugnot JP, et al. (2012). Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells. Br J Cancer 107:1488-1497.
27. Lynge E, Sandegaard JL, Rebolj M (2011). The Danish National Patient Register. Scand J Public Health 39:30-33.
28. Morrison BW, Doudican NA, Patel KR, Orlow SJ (2010). Disulfiram induces copper-dependent stimulation of reactive oxygen species and activation of the extrinsic apoptotic pathway in melanoma. Melanoma Res 20:11-20.
29. Outzen M, Brasso K, Martinussen N, Christensen J, Tjonneland A, Friis S, et al. (2013). Prostate cancer in Denmark 1978-2. Acta Oncol 52:831-836.
30. Pedersen CB (2011). The Danish Civil Registration System. Scand J Public Health 39:22-25.
31. Rothman KJ, Greenland S, Lash TL (2008). Modern epidemiology. 3rd ed. Philadelphia: Wolters Kluwer Health, Lippincott Williams & Wilkins.
32. Secretan B, Straif K, Baan R, Grosse Y, El GF, Bouvard V, et al. (2009). A review of human carcinogens-part E: Tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol 10:1033-1034.
33. Storm HH, Michelsen EV, Clemmensen IH, Pihl J (1997). The Danish Cancer Registry-history, content, quality and use. Dan Med Bull 44:535-539.
34. Suh JJ, Pettinati HM, Kampman KM, O'Brien CP (2006). The status of disulfiram: A half of a century later. J Clin Psychopharmacol 26:290-302.
35. Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sorensen HT (2011). The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Med Res Methodol 11:83.
36. Verma S, Stewart DJ, Maroun JA, Nair RC (1990). A randomized phase II study of cisplatin alone versus cisplatin plus disulfiram. Am J Clin Oncol 13:119-124.
37. Volkovova K, Bilanicova D, Bartonova A, Letasiova S, Dusinska M (2012). Associations between environmental factors and incidence of cutaneous melanoma. Review. Environ Health 11 (Suppl 1):S12.
38. WHO Collaborating Centre for Drug Statistics Methodology (2012). Guidelines for ATC classification and DDD assignment 2013. Oslo: WHO Collaborating Centre for Drug Statistics Methodology.
39. Yip NC, Fombon IS, Liu P, Brown S, Kannappan V, Armesilla AL, et al. (2011). Disulfiram modulated ROS-MAPK and NFkappaB pathways and targeted breast cancer cells with cancer stem cell-like properties. Br J Cancer 104:1564-1574.
40. Zhang H, Chen D, Ringler J, Chen W, Cui QC, Ethier SP, et al. (2010). Disulfiram treatment facilitates phosphoinositide 3-kinase inhibition in human breast cancer cells in vitro and in vivo. Cancer Res 70:3996-4004.